<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">39319014</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>12</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2190-572X</ISSN><JournalIssue CitedMedium="Print"><Volume>14</Volume><Issue>10</Issue><PubDate><Year>2024</Year><Month>Oct</Month></PubDate></JournalIssue><Title>3 Biotech</Title><ISOAbbreviation>3 Biotech</ISOAbbreviation></Journal><ArticleTitle>From ancient remedies to modern miracles: tracing the evolution of vaccines and their impact on public health.</ArticleTitle><Pagination><StartPage>242</StartPage><MedlinePgn>242</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">242</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1007/s13205-024-04075-7</ELocationID><Abstract><AbstractText>This review traces the development of vaccines from ancient times to the present, highlighting major milestones and challenges. It covers the significant impact of vaccines on public health, including the eradication of diseases such as smallpox and the reduction of others such as polio, measles, and influenza. The review provides an in-depth look at the COVID-19 vaccines, which were developed at unprecedented speeds due to the urgent global need. The study emphasizes the ongoing potential of vaccine development to address future global health challenges, demonstrating the critical role vaccines play in disease prevention and public health. Moreover, it discusses the evolution of vaccine technology, from live-attenuated and inactivated vaccines to modern recombinant and mRNA vaccines, showcasing the advancements that have enabled rapid responses to emerging infectious diseases. The review underscores the importance of continued investment in research and development, global collaboration, and the adoption of new technologies to enhance vaccine efficacy and coverage. By exploring historical and contemporary examples, the article illustrates how vaccines have transformed medical practice and public health outcomes, providing valuable insights into future directions for vaccine innovation and deployment.</AbstractText><CopyrightInformation>© King Abdulaziz City for Science and Technology 2024. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Kajal</LastName><AffiliationInfo><Affiliation>School of Biosciences &amp; Technology, Galgotias University, Gautam Buddha Nagar, Greater Noida, Uttar Pradesh 203201 India.</Affiliation><Identifier Source="ROR">https://ror.org/02w8ba206</Identifier><Identifier Source="GRID">grid.448824.6</Identifier><Identifier Source="ISNI">0000 0004 1786 549X</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pandey</LastName><ForeName>Achyut</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>School of Biosciences &amp; Technology, Galgotias University, Gautam Buddha Nagar, Greater Noida, Uttar Pradesh 203201 India.</Affiliation><Identifier Source="ROR">https://ror.org/02w8ba206</Identifier><Identifier Source="GRID">grid.448824.6</Identifier><Identifier Source="ISNI">0000 0004 1786 549X</Identifier></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mishra</LastName><ForeName>Shruti</ForeName><Initials>S</Initials><Identifier Source="ORCID">0000-0002-2846-0135</Identifier><AffiliationInfo><Affiliation>School of Biosciences &amp; Technology, Galgotias University, Gautam Buddha Nagar, Greater Noida, Uttar Pradesh 203201 India.</Affiliation><Identifier Source="ROR">https://ror.org/02w8ba206</Identifier><Identifier Source="GRID">grid.448824.6</Identifier><Identifier Source="ISNI">0000 0004 1786 549X</Identifier></AffiliationInfo><AffiliationInfo><Affiliation>School of Biotechnology, Jawaharlal Nehru University, New Delhi, India.</Affiliation><Identifier Source="ROR">https://ror.org/0567v8t28</Identifier><Identifier Source="GRID">grid.10706.30</Identifier><Identifier Source="ISNI">0000 0004 0498 924X</Identifier></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>09</Month><Day>22</Day></ArticleDate></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>3 Biotech</MedlineTA><NlmUniqueID>101565857</NlmUniqueID><ISSNLinking>2190-5738</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Cholera</Keyword><Keyword MajorTopicYN="N">Influenza</Keyword><Keyword MajorTopicYN="N">Shigella</Keyword><Keyword MajorTopicYN="N">Typhoid</Keyword><Keyword MajorTopicYN="N">Vaccines</Keyword></KeywordList><CoiStatement>Conflict of interestThe authors declare no conflict of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>4</Month><Day>7</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>30</Day></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>10</Hour><Minute>19</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>10</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>25</Day><Hour>4</Hour><Minute>27</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39319014</ArticleId><ArticleId IdType="pmc">PMC11417089</ArticleId><ArticleId IdType="doi">10.1007/s13205-024-04075-7</ArticleId><ArticleId IdType="pii">4075</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Akama K, Kameyama S, Otani S, Sadahiro S, Murata R (1971) Reversion of toxicity of diphtheria toxoid. Jpn J Med Sci Biol 24(3):183–187. 10.7883/yoken1952.24.183</Citation><ArticleIdList><ArticleId IdType="pubmed">5315160</ArticleId></ArticleIdList></Reference><Reference><Citation>Antillón M, Warren JL, Crawford FW, Weinberger DM, Kürüm E, Pak GD, Marks F, Pitzer VE (2017) The burden of typhoid fever in low- and middle-income countries: a meta-regression approach. PLOS Negl Trop Dis 11(2):e0005376. 10.1371/journal.pntd.0005376</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5344533</ArticleId><ArticleId IdType="pubmed">28241011</ArticleId></ArticleIdList></Reference><Reference><Citation>Bartlett J, Borio L, Radonovich L, Mair JS, O’Toole T, Mair M, Halsey N, Grow R, Inglesby TV (2003) Smallpox vaccination in 2003: key information for clinicians. Clin Infect Dis 36(7):883–902. 10.1086/374792</Citation><ArticleIdList><ArticleId IdType="pubmed">12652390</ArticleId></ArticleIdList></Reference><Reference><Citation>Bernstein D (1998) Safety and immunogenicity of live, attenuated human rotavirus vaccine 89–12. Vaccine 16(4):381–387. 10.1016/S0264-410X(97)00210-7</Citation><ArticleIdList><ArticleId IdType="pubmed">9607059</ArticleId></ArticleIdList></Reference><Reference><Citation>Boddice R (ed) (2023) Scientific and Medical Knowledge Production, 1796-1918: Volume II: Humanity. Taylor &amp; Francis</Citation></Reference><Reference><Citation>Bröker M, Berti F, Schneider J, Vojtek I (2017) Polysaccharide conjugate vaccine protein carriers as a ‘neglected valency’—potential and limitations. Vaccine 35(25):3286–3294. 10.1016/j.vaccine.2017.04.078</Citation><ArticleIdList><ArticleId IdType="pubmed">28487056</ArticleId></ArticleIdList></Reference><Reference><Citation>Buynak EB, Weibel RE, Whitman JE, Stokes J, Hilleman MR (1969) Combined live measles, mumps, and rubella virus vaccines. JAMA 207(12):2259–2262</Citation><ArticleIdList><ArticleId IdType="pubmed">5818433</ArticleId></ArticleIdList></Reference><Reference><Citation>Buynak EB, Roehm RR, Tytell AA, Bertland AU, Lampson GP, Hilleman MR (1976) Vaccine against Human Hepatitis B. JAMA 235(26):2832–2834</Citation><ArticleIdList><ArticleId IdType="pubmed">819667</ArticleId></ArticleIdList></Reference><Reference><Citation>Capeding MR, Teshome S, Saluja T, Syed KA, Kim DR, Park JY, Yang JS et al (2018) Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: phase I trial in healthy filipino adults and children. Vaccine 36(26):3794–3801. 10.1016/j.vaccine.2018.05.038</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6005168</ArticleId><ArticleId IdType="pubmed">29776750</ArticleId></ArticleIdList></Reference><Reference><Citation>Capeding MR, Alberto E, Sil A, Saluja T, Teshome S, Kim DR, Park JY et al (2020) Immunogenicity, safety and reactogenicity of a phase II Trial of Vi-DT typhoid conjugate vaccine in healthy filipino infants and toddlers: a preliminary report. Vaccine 38(28):4476–4483. 10.1016/j.vaccine.2019.09.074</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7273193</ArticleId><ArticleId IdType="pubmed">31585725</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr S, Miller J, Leary SEC, Bennett AM, Ho A, Williamson ED (1999) Expression of a recombinant form of the v antigen of yersinia pestis, using three different expression systems. Vaccine 18(1–2):153–159. 10.1016/S0264-410X(99)00214-5</Citation><ArticleIdList><ArticleId IdType="pubmed">10501245</ArticleId></ArticleIdList></Reference><Reference><Citation>Cenna J, Tan GS, Papaneri AB, Dietzschold B, Schnell MJ, McGettigan JP (2008) Immune modulating effect by a phosphoprotein-deleted rabies virus vaccine vector expressing two copies of the rabies virus glycoprotein gene. Vaccine 26(50):6405–6414. 10.1016/j.vaccine.2008.08.069</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2629409</ArticleId><ArticleId IdType="pubmed">18804506</ArticleId></ArticleIdList></Reference><Reference><Citation>Cenna J, Hunter M, Tan GS, Papaneri AB, Ribka EP, Schnell MJ, Marx PA, McGettigan JP (2009) Replication-deficient rabies virus-based vaccines are safe and immunogenic in mice and nonhuman primates. J Infect Dis 200(8):1251–1260. 10.1086/605949</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3388800</ArticleId><ArticleId IdType="pubmed">19764884</ArticleId></ArticleIdList></Reference><Reference><Citation>Charney J, Tytell AA, Machlowitz RA, Hilleman MR (1961) Development of a purified poliomyelitis virus vaccine. JAMA 177(9):591–595</Citation><ArticleIdList><ArticleId IdType="pubmed">13692508</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemens J (1988) Impact of B subunit killed whole-cell and killed whole-cell-only oral vaccines against cholera upon treated diarrhoeal illness and mortality in an area endemic for cholera. Lancet 331(8599):1375–1379. 10.1016/S0140-6736(88)92189-7</Citation><ArticleIdList><ArticleId IdType="pubmed">2898052</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemens J (1990) Field trial of oral cholera vaccines in bangladesh: results from three-year follow-up. Lancet 335(8684):270–273. 10.1016/0140-6736(90)90080-O</Citation><ArticleIdList><ArticleId IdType="pubmed">1967730</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemens JD, Harris JR, Sack DA, Chakraborty J, Ahmed F, Stanton BF, Khan MU et al (1988) Field trial of oral cholera vaccines in bangladesh: results of one year of follow-up. J Infect Dis 158(1):60–69. 10.1093/infdis/158.1.60</Citation><ArticleIdList><ArticleId IdType="pubmed">3392421</ArticleId></ArticleIdList></Reference><Reference><Citation>Clemens JD, Van Loon F, Sack DA, Chakraborty J, Rao MR, Ahmed F, Harris JR et al (1991) Field trial of oral cholera vaccines in bangladesh: serum vibriocidal and antitoxic antibodies as markers of the risk of cholera. J Infect Dis 163(6):1235–1242. 10.1093/infdis/163.6.1235</Citation><ArticleIdList><ArticleId IdType="pubmed">2037789</ArticleId></ArticleIdList></Reference><Reference><Citation>Crump JA, Sjölund-Karlsson M, Gordon MA, Parry CM (2015) Epidemiology, clinical presentation, laboratory diagnosis, antimicrobial resistance, and antimicrobial management of invasive salmonella infections. Clin Microbiol Rev 28(4):901–937. 10.1128/CMR.00002-15</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4503790</ArticleId><ArticleId IdType="pubmed">26180063</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui C, Carbis R, An SJ, Jang H, Czerkinsky C, Szu SC, Clemens JD (2010) Physical and chemical characterization and immunologic properties of Salmonella Enterica Serovar Typhi capsular polysaccharide-diphtheria toxoid conjugates. Clin Vaccine Immunol 17(1):73–79. 10.1128/CVI.00266-09</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2812100</ArticleId><ArticleId IdType="pubmed">19889941</ArticleId></ArticleIdList></Reference><Reference><Citation>Darton TC, Jones C, Blohmke CJ, Waddington CS, Zhou L, Peters Anna, Haworth K et al (2016) Using a human challenge model of infection to measure vaccine efficacy: a randomised, controlled trial comparing the typhoid vaccines M01ZH09 with placebo and Ty21a. PLOS Negl Trop Dis 10(8):e0004926. 10.1371/journal.pntd.0004926</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4988630</ArticleId><ArticleId IdType="pubmed">27533046</ArticleId></ArticleIdList></Reference><Reference><Citation>Date KA, Bentsi-Enchill A, Marks F, Fox K (2015) Typhoid fever vaccination strategies. Vaccine 33(Suppl 3):C55–C61. 10.1016/j.vaccine.2015.04.028</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10644681</ArticleId><ArticleId IdType="pubmed">25902360</ArticleId></ArticleIdList></Reference><Reference><Citation>Diane Williamson E, Eley SM, Stagg AJ, Green M, Russell P, Titball RW (1997) A sub-unit vaccine elicits IgG in serum, spleen cell cultures and bronchial washings and protects immunized animals against pneumonic plague. Vaccine 15(10):1079–1084. 10.1016/S0264-410X(96)00303-9</Citation><ArticleIdList><ArticleId IdType="pubmed">9269050</ArticleId></ArticleIdList></Reference><Reference><Citation>Dinh TV, Lin F-Y, Canh DG, Son NH, Anh DD, Mao ND, Chu C et al (2011) The Vi Conjugate Typhoid vaccine is safe, elicits protective levels of IgG Anti-Vi, and is compatible with routine infant vaccines. Clin Vaccine Immunol 18(5):730–735. 10.1128/CVI.00532-10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3122535</ArticleId><ArticleId IdType="pubmed">21411598</ArticleId></ArticleIdList></Reference><Reference><Citation>Elvin SJ, Williamson ED (2000) The F1 and V subunit vaccine protects against plague in the absence of IL-4 driven immune responses. Microb Pathog 29(4):223–230. 10.1006/mpat.2000.0385</Citation><ArticleIdList><ArticleId IdType="pubmed">10993741</ArticleId></ArticleIdList></Reference><Reference><Citation>Enders JF, Katz SL, Milovanovic MV, Holloway A (1960) Studies on an attenuated measles-virus vaccine: development and preparation of the vaccine: technics for assay of effects of vaccination. N Engl J Med 263(4):153–159. 10.1056/NEJM196007282630401</Citation><ArticleIdList><ArticleId IdType="pubmed">13820246</ArticleId></ArticleIdList></Reference><Reference><Citation>Engels, Ea, and J Lau. 1998. “Vaccines for preventing typhoid fever.” In Cochrane database of systematic reviews, edited by The Cochrane Collaboration, CD001261. Chichester, UK: John Wiley and Sons, Ltd. 10.1002/14651858.CD001261.</Citation></Reference><Reference><Citation>Fenner F (ed) (1988) Smallpox and its eradication. history of international public health, no. 6. World Health Organization, Geneva</Citation></Reference><Reference><Citation>Fogg C, Shlomo Lustig J, Whitbeck C, Eisenberg RJ, Cohen GH, Moss B (2004) Protective immunity to vaccinia virus induced by vaccination with multiple recombinant outer membrane proteins of intracellular and extracellular virions. J Virol 78(19):10230–10237. 10.1128/JVI.78.19.10230-10237.2004</Citation><ArticleIdList><ArticleId IdType="pmc">PMC516428</ArticleId><ArticleId IdType="pubmed">15367588</ArticleId></ArticleIdList></Reference><Reference><Citation>Frederick DR, Goggins JA, Sabbagh LM, Freytag LC, Clements JD, McLachlan JB (2018) Adjuvant selection regulates gut migration and phenotypic diversity of antigen-specific CD4+ T Cells following parenteral immunization. Mucosal Immunol 11(2):549–561. 10.1038/mi.2017.70</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6252260</ArticleId><ArticleId IdType="pubmed">28792004</ArticleId></ArticleIdList></Reference><Reference><Citation>Frey SE, Newman FK, John Cruz W, Shelton B, Tennant JM, Polach T, Rothman AL et al (2002) Dose-related effects of smallpox vaccine. N Engl J Med 346(17):1275–1280. 10.1056/NEJMoa013431</Citation><ArticleIdList><ArticleId IdType="pubmed">11923489</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghattas M, Dwivedi G, Lavertu M, Alameh M-G (2021) Vaccine technologies and platforms for infectious diseases: current progress, challenges, and opportunities. Vaccines 9(12):1490. 10.3390/vaccines9121490</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8708925</ArticleId><ArticleId IdType="pubmed">34960236</ArticleId></ArticleIdList></Reference><Reference><Citation>Glenny AT, Hopkins BE (1923) Diphtheria toxoid as an immunising agent. Br J Exp Pathol 4(5):283</Citation></Reference><Reference><Citation>Gold R (1986) Pertussis: the disease and the vaccine. Canadian Family Physician Medecin De Famille Canadien 32:79–83</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2327589</ArticleId><ArticleId IdType="pubmed">21274243</ArticleId></ArticleIdList></Reference><Reference><Citation>Griffin TJ, Thanawastien A, Cartee RT, Mekalanos JJ, Killeen KP (2019) In vitro characterization and preclinical immunogenicity of Typhax, a typhoid fever protein capsular matrix vaccine candidate. Hum Vaccin Immunother 15(6):1310–1316. 10.1080/21645515.2019.1599674</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6663131</ArticleId><ArticleId IdType="pubmed">31021700</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta S, Pellett S (2023) Recent developments in vaccine design: from live vaccines to recombinant toxin vaccines. Toxins 15(9):563. 10.3390/toxins15090563</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10536331</ArticleId><ArticleId IdType="pubmed">37755989</ArticleId></ArticleIdList></Reference><Reference><Citation>Gupta RK, Taylor DN, Bryla DA, Robbins JB, Szu SC (1998) Phase 1 evaluation of Vibrio Cholerae O1, serotype inaba, polysaccharide-cholera toxin conjugates in adult volunteers. Infect Immun 66(7):3095–3099. 10.1128/IAI.66.7.3095-3099.1998</Citation><ArticleIdList><ArticleId IdType="pmc">PMC108318</ArticleId><ArticleId IdType="pubmed">9632571</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall RH (2018) Curbing cholera. Sci Transl Med 10(445):9483. 10.1126/scitranslmed.aat9483</Citation><ArticleIdList><ArticleId IdType="pubmed">29899025</ArticleId></ArticleIdList></Reference><Reference><Citation>Halsey NA (2002) The science of evaluation of adverse events associated with vaccination. Semin Pediat Infect Dis 13(3):205–214. 10.1053/spid.2002.125864</Citation><ArticleIdList><ArticleId IdType="pubmed">12199617</ArticleId></ArticleIdList></Reference><Reference><Citation>Helting TB, Blackkolb F (1981) Extracted protective antigen of bordetella pertussis I preparation and properties of the solubilized surface of components. Acta Pathol Microbiol Scand 89(2):93–101</Citation><ArticleIdList><ArticleId IdType="pubmed">6266198</ArticleId></ArticleIdList></Reference><Reference><Citation>Hemert V, Van PaulWezel Cohen ALHH (1964) Preparation of soluble pertussis vaccine. Nature 203(4946):774–775. 10.1038/203774a0</Citation><ArticleIdList><ArticleId IdType="pubmed">14207294</ArticleId></ArticleIdList></Reference><Reference><Citation>Henderson DA, Inglesby TV, Bartlett JG, Ascher MS, Eitzen E, Jahrling PB, Hauer J et al (1999) Smallpox as a biological weapon: medical and public health management. working group on civilian biodefense. JAMA 281(22):2127–2137. 10.1001/jama.281.22.2127</Citation><ArticleIdList><ArticleId IdType="pubmed">10367824</ArticleId></ArticleIdList></Reference><Reference><Citation>Hewlett EL, Manclark CR, Wolff J (1977) Adenyl cyclase in bordetella pertussis vaccines. The Journal of Infectious Diseases 136(1):S216-219. 10.1093/infdis/136.supplement.s216</Citation><ArticleIdList><ArticleId IdType="pubmed">19542</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilleman MR (1998a) Discovery of simian virus 40 (SV40) and its relationship to poliomyelitis virus vaccines. Dev Biol Stand 94:183–190</Citation><ArticleIdList><ArticleId IdType="pubmed">9776239</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilleman MR (1998b) Six decades of vaccine development—a personal history. Nat Med 4(5 Suppl):507–514. 10.1038/nm0598supp-507</Citation><ArticleIdList><ArticleId IdType="pubmed">9585201</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilleman MR (1999a) Personal historical chronicle of six decades of basic and applied research in virology, immunology, and vaccinology. Immunol Rev 170(August):7–27. 10.1111/j.1600-065x.1999.tb01325.x</Citation><ArticleIdList><ArticleId IdType="pubmed">10566138</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilleman MR, Weibel RE, Buynak EB, Stokes J, Whitman JE (1967a) Live, attenuated mumps-virus vaccine. IV. Protective efficacy as measured in a field evaluation. N Engl J Med 276(5):252–258. 10.1056/NEJM196702022760502</Citation><ArticleIdList><ArticleId IdType="pubmed">6016061</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilleman MR, Weibel RE, Buynak EB, Stokes J, Whitman JE (1967b) Live, attenuated mumps-virus vaccine: protective efficacy as measured in a field evaluation. N Engl J Med 276(5):252–258. 10.1056/NEJM196702022760502</Citation><ArticleIdList><ArticleId IdType="pubmed">6016061</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilleman MR, Buynak EB, Roehm RR, Tytell AA, Bertland AU, Lampson GP (1975) Purified and inactivated human Hepatitis B vaccine: progress report. Am J Med Sci 270(2):401–404. 10.1097/00000441-197509000-00025</Citation><ArticleIdList><ArticleId IdType="pubmed">828833</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilleman, M. R., J. Stokes, E. B. Buynak, R. Weibel, R. Halenda, and H. Goldner. 1962. “Studies of Live Attenuated Measles Virus Vaccine in Man. II. Appraisal of Efficacy.” American Journal of Public Health and the Nation’s Health 52(2)Suppl (Suppl 2): 44–56. 10.2105/ajph.52.suppl_2.44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1522574</ArticleId><ArticleId IdType="pubmed">13907411</ArticleId></ArticleIdList></Reference><Reference><Citation>Hilleman, Maurice R (1999) “Combined measles, mumps, and rubella vaccines.” In Combination vaccines, edited by Ronald W. Ellis, 197–211. Totowa, NJ: Humana Press. 10.1007/978-1-59259-265-4_9.</Citation></Reference><Reference><Citation>Hohmann EL, Oletta CA, Killeen KP, Miller SI (1996) phoP/phoQ-deleted Salmonella Typhi (Ty800) is a safe and immunogenic single-dose typhoid fever vaccine in volunteers. J Infect Dis 173(6):1408–1414. 10.1093/infdis/173.6.1408</Citation><ArticleIdList><ArticleId IdType="pubmed">8648213</ArticleId></ArticleIdList></Reference><Reference><Citation>Hooper JW, Thompson E, Wilhelmsen C, Zimmerman M, Ait Ichou M, Steffen SE, Schmaljohn CS, Schmaljohn AL, Jahrling PB (2004) Smallpox DNA vaccine protects nonhuman primates against Lethal Monkeypox. J Virol 78(9):4433–4443. 10.1128/jvi.78.9.4433-4443.2004</Citation><ArticleIdList><ArticleId IdType="pmc">PMC387704</ArticleId><ArticleId IdType="pubmed">15078924</ArticleId></ArticleIdList></Reference><Reference><Citation>Hubbard TP, Billings G, Dörr T, Sit B, Warr AR, Kuehl CJ, Kim M et al (2018) A live vaccine rapidly protects against cholera in an infant rabbit model. Sci Transl Med 10(445):8423. 10.1126/scitranslmed.aap8423</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6500431</ArticleId><ArticleId IdType="pubmed">29899024</ArticleId></ArticleIdList></Reference><Reference><Citation>Hughes WF, Watanabe DH, Rubin H (1963) The development of a chicken flock apparently free of Leukosis Virus. Avian Dis 7(2):154. 10.2307/1588044</Citation></Reference><Reference><Citation>Hussain A, Yang H, Zhang M, Liu Q, Alotaibi G, Irfan M, He H et al (2022) mRNA Vaccines for COVID-19 and diverse diseases. J Control Release 345(May):314–333. 10.1016/j.jconrel.2022.03.032</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8935967</ArticleId><ArticleId IdType="pubmed">35331783</ArticleId></ArticleIdList></Reference><Reference><Citation>Islam N, Sheils NE, Jarvis MS, Cohen K (2022) Comparative Effectiveness over time of the mRNA-1273 (Moderna) vaccine and the BNT162b2 (Pfizer-BioNTech) vaccine. Nat Commun 13(1):2377. 10.1038/s41467-022-30059-3</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9061778</ArticleId><ArticleId IdType="pubmed">35501319</ArticleId></ArticleIdList></Reference><Reference><Citation>Ivanoff B, Levine MM, Lambert PH (1994) Vaccination against typhoid fever: present status. Bull World Health Organ 72(6):957–971</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2486740</ArticleId><ArticleId IdType="pubmed">7867143</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones SM, Day F, Stagg AJ, Williamson ED (2000) Protection conferred by a fully recombinant sub-unit vaccine against yersinia pestis in male and female mice of four inbred strains. Vaccine 19(2–3):358–366. 10.1016/s0264-410x(00)00108-0</Citation><ArticleIdList><ArticleId IdType="pubmed">10930691</ArticleId></ArticleIdList></Reference><Reference><Citation>Karzon DT, Henderson DA (1966) Current Status of Live Attenuated Virus Vaccines. Adv Pediatr 14(1):121–200. 10.1016/S0065-3101(22)00503-5</Citation><ArticleIdList><ArticleId IdType="pubmed">5330506</ArticleId></ArticleIdList></Reference><Reference><Citation>Kenner J, Cameron F, Empig C, Jobes DV, Gurwith M (2006) LC16m8: an attenuated smallpox vaccine. Vaccine 24(47–48):7009–7022. 10.1016/j.vaccine.2006.03.087</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7115618</ArticleId><ArticleId IdType="pubmed">17052815</ArticleId></ArticleIdList></Reference><Reference><Citation>Kier LD, Weppelman RM, Ames BN (1979) Regulation of nonspecific acid phosphatase in Salmonella: phoN and phoP genes. J Bacteriol 138(1):155–161. 10.1128/jb.138.1.155-161.1979</Citation><ArticleIdList><ArticleId IdType="pmc">PMC218252</ArticleId><ArticleId IdType="pubmed">374361</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirk MD, Pires SM, Black RE, Caipo M, Crump JA, Devleesschauwer B, Döpfer D et al (2015) World Health Organization estimates of the global and regional disease burden of 22 Foodborne Bacterial, Protozoal, and viral diseases, 2010: a data synthesis. PLoS Med 12(12):e1001921. 10.1371/journal.pmed.1001921</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4668831</ArticleId><ArticleId IdType="pubmed">26633831</ArticleId></ArticleIdList></Reference><Reference><Citation>Kossaczka Z, Lin FYC, Ho VA, Thuy NTT, Van Bay P, Thanh TC, Khiem HB et al (1999) Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 67(11):5806–10. 10.1128/IAI.67.11.5806-5810.1999</Citation><ArticleIdList><ArticleId IdType="pmc">PMC96958</ArticleId><ArticleId IdType="pubmed">10531232</ArticleId></ArticleIdList></Reference><Reference><Citation>Kossaczka Z, Lin FY, Ho VA, Thuy NT, Van Bay P, Thanh TC, Khiem HB et al (1999) Safety and immunogenicity of Vi conjugate vaccines for typhoid fever in adults, teenagers, and 2- to 4-year-old children in Vietnam. Infect Immun 67(11):5806–5810. 10.1128/IAI.67.11.5806-5810.1999</Citation><ArticleIdList><ArticleId IdType="pmc">PMC96958</ArticleId><ArticleId IdType="pubmed">10531232</ArticleId></ArticleIdList></Reference><Reference><Citation>Kuchta A, Rahman T, Sennott EL, Bhuyian TR, Uddin T, Rashu R, Chowdhury F et al (2011) Vibrio Cholerae O1 infection induces proinflammatory CD4+ T-Cell responses in blood and intestinal mucosa of infected humans. Clin Vaccine Immunol 18(8):1371–1377. 10.1128/CVI.05088-11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3147337</ArticleId><ArticleId IdType="pubmed">21697339</ArticleId></ArticleIdList></Reference><Reference><Citation>Lebens M, Karlsson SL, Källgård S, Blomquist M, Ekman A, Nygren E, Holmgren J (2011) Construction of novel vaccine strains of vibrio cholerae co-expressing the Inaba and Ogawa serotype antigens. Vaccine 29(43):7505–7513. 10.1016/j.vaccine.2011.06.121</Citation><ArticleIdList><ArticleId IdType="pubmed">21807059</ArticleId></ArticleIdList></Reference><Reference><Citation>Leitner DR, Lichtenegger S, Temel P, Zingl FG, Ratzberger D, Roier S, Schild-Prüfert K, Feichter S, Reidl J, Schild S (2015) A combined vaccine approach against vibrio cholerae and ETEC based on outer membrane vesicles. Front Microbiol 6:823. 10.3389/fmicb.2015.00823</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4531250</ArticleId><ArticleId IdType="pubmed">26322032</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung DT, Rahman MA, Mohasin M, Patel SM, Aktar A, Khanam F, Uddin T et al (2012) Memory B cell and other immune responses in children receiving two doses of an oral killed cholera vaccine compared to responses following natural cholera infection in Bangladesh. Clin Vaccine Immunol 19(5):690–698. 10.1128/CVI.05615-11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3346319</ArticleId><ArticleId IdType="pubmed">22441386</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine MM, Kaper JB, Herrington D, Ketley J, Losonsky G, Tacket CO, Tall B, Cryz S (1988) Safety, immunogenicity, and efficacy of recombinant live oral cholera vaccines, CVD 103 and CVD 103-HgR. Lancet (London, England) 2(8609):467–470. 10.1016/s0140-6736(88)90120-1</Citation><ArticleIdList><ArticleId IdType="pubmed">2900401</ArticleId></ArticleIdList></Reference><Reference><Citation>Levine MM, Ferreccio C, Black RE, Tacket CO, Germanier R (1989) Progress in vaccines against typhoid fever. Rev Infect Dis 11(Suppl 3):S552–S567. 10.1093/clinids/11.supplement_3.s552</Citation><ArticleIdList><ArticleId IdType="pubmed">2669099</ArticleId></ArticleIdList></Reference><Reference><Citation>Madsen T (1933) Vaccination against whooping cough. JAMA 101(3):187. 10.1001/jama.1933.02740280007003</Citation></Reference><Reference><Citation>Mascoli CC, Ittensohn OL, Villarejos VM, Arguedas JA, Provost PJ, Hilleman MR (1973) Recovery of Hepatitis agents in the marmoset from human cases occurring in Costa Rica. Proc Soc Exp Biol Med 142(1):276–82. 10.3181/00379727-142-37005</Citation><ArticleIdList><ArticleId IdType="pubmed">4630292</ArticleId></ArticleIdList></Reference><Reference><Citation>Mayo-Smith LM, Simon JK, Chen WH, Haney D, Lock M, Lyon CE, Calderwood SB et al (2017) The live attenuated cholera vaccine CVD 103-HgR primes responses to the Toxin-Coregulated Pilus Antigen TcpA in subjects challenged with wild-type vibrio cholerae. Clin Vaccine Immunol 24(1):e00470-e516. 10.1128/CVI.00470-16</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5216439</ArticleId><ArticleId IdType="pubmed">27847368</ArticleId></ArticleIdList></Reference><Reference><Citation>McLean AA (1986) Development of vaccines against Hepatitis A and Hepatitis B. Clin Infect Dis 8(4):591–598. 10.1093/clinids/8.4.591</Citation><ArticleIdList><ArticleId IdType="pubmed">3018891</ArticleId></ArticleIdList></Reference><Reference><Citation>Mebatsion T, Weiland F, Conzelmann KK (1999) Matrix protein of rabies virus is responsible for the assembly and budding of bullet-shaped particles and interacts with the transmembrane Spike Glycoprotein G. J Virol 73(1):242–250. 10.1128/JVI.73.1.242-250.1999</Citation><ArticleIdList><ArticleId IdType="pmc">PMC103828</ArticleId><ArticleId IdType="pubmed">9847327</ArticleId></ArticleIdList></Reference><Reference><Citation>Medise BE, Soedjatmiko S, Rengganis I, Gunardi H, Sekartini R, Koesno S, Satari HI et al (2019) Six-month follow up of a randomized clinical trial-phase i study in indonesian adults and children: safety and immunogenicity of Salmonella Typhi Polysaccharide-Diphtheria Toxoid (Vi-DT) conjugate vaccine. PLOS One 14(2):e0211784. 10.1371/journal.pone.0211784</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6373931</ArticleId><ArticleId IdType="pubmed">30759132</ArticleId></ArticleIdList></Reference><Reference><Citation>Meiring JE, Gibani M, TyVAC Consortium Meeting Group (2017) The Typhoid Vaccine Acceleration Consortium (TyVAC): vaccine effectiveness study designs: accelerating the introduction of typhoid conjugate vaccines and reducing the global burden of enteric fever. Report from a Meeting Held on 26-27 October 2016, Oxford, UK. Vaccine 35(38):5081–88. 10.1016/j.vaccine.2017.08.001</Citation><ArticleIdList><ArticleId IdType="pubmed">28802757</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer KF (1970) Effectiveness of live or killed plague vaccines in man. Bull World Health Organ 42(5):653–666</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2427500</ArticleId><ArticleId IdType="pubmed">4988692</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer KF, Cavanaugh DC, Bartelloni PJ, Marshall JD (1974) Plague immunization. I. Past and present trends. J Infect Dis 129:S13–S18. 10.1093/infdis/129.supplement_1.s13</Citation><ArticleIdList><ArticleId IdType="pubmed">4596516</ArticleId></ArticleIdList></Reference><Reference><Citation>Meyer KF, Smith G, Foster L, Brookman M, Sung M (1974) Live, Attenuated Yersinia Pestis Vaccine: virulent in Nonhuman primates, harmless to Guinea Pigs. J Infect Dis 129:S85–S120. 10.1093/infdis/129.supplement_1.s85</Citation><ArticleIdList><ArticleId IdType="pubmed">4207627</ArticleId></ArticleIdList></Reference><Reference><Citation>Micoli F, Rondini S, Pisoni I, Proietti D, Berti F, Costantino P, Rappuoli R, Szu S, Saul A, Martin LB (2011) Vi-CRM 197 as a new conjugate vaccine against Salmonella Typhi. Vaccine 29(4):712–720. 10.1016/j.vaccine.2010.11.022</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4163788</ArticleId><ArticleId IdType="pubmed">21115057</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller SI, Kukral AM, Mekalanos JJ (1989) A two-component regulatory system (phoP phoQ) controls Salmonella Typhimurium Virulence. Proc Natl Acad Sci USA 86(13):5054–5058. 10.1073/pnas.86.13.5054</Citation><ArticleIdList><ArticleId IdType="pmc">PMC297555</ArticleId><ArticleId IdType="pubmed">2544889</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller J, Williamson ED, Lakey JH, Pearce MJ, Jones SM, Titball RW (1998) Macromolecular organisation of recombinant Yersinia Pestis F1 antigen and the effect of structure on immunogenicity. FEMS Immunol Med Microbiol 21(3):213–221. 10.1111/j.1574-695X.1998.tb01168.x</Citation><ArticleIdList><ArticleId IdType="pubmed">9718211</ArticleId></ArticleIdList></Reference><Reference><Citation>Miller, Mark, Scott Barrett, and D. A. Henderson. 2006. “Control and Eradication.” In Disease control priorities in developing countries, edited by Dean T. Jamison, Joel G. Breman, Anthony R. Measham, George Alleyne, Mariam Claeson, David B. Evans, Prabhat Jha, Anne Mills, and Philip Musgrove, 2nd edn. Washington (DC): The International Bank for Reconstruction and Development/The World Bank. http://www.ncbi.nlm.nih.gov/books/NBK11763/.</Citation><ArticleIdList><ArticleId IdType="pubmed">21250309</ArticleId></ArticleIdList></Reference><Reference><Citation>Minor PD (2015) Live attenuated vaccines: historical successes and current challenges. Virology 479–480(May):379–392. 10.1016/j.virol.2015.03.032</Citation><ArticleIdList><ArticleId IdType="pubmed">25864107</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitra M, Shah N, Ghosh A, Chatterjee S, Kaur I, Bhattacharya N, Basu S (2016) Efficacy and safety of Vi-Tetanus Toxoid Conjugated Typhoid Vaccine (PedaTyph™) in Indian children: school based cluster randomized study. Hum Vaccin Immunother 12(4):939–945. 10.1080/21645515.2015.1117715</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4962969</ArticleId><ArticleId IdType="pubmed">26901576</ArticleId></ArticleIdList></Reference><Reference><Citation>Mogasale V, Brian Maskery R, Ochiai L, Lee JS, Mogasale VV, Ramani E, Kim YE, Park JK, Wierzba TF (2014) Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment. Lancet Glob Health 2(10):e570-580. 10.1016/S2214-109X(14)70301-8</Citation><ArticleIdList><ArticleId IdType="pubmed">25304633</ArticleId></ArticleIdList></Reference><Reference><Citation>Monath Thomas P, Caldwell Joseph R, Mundt Wolfgang, Fusco Joan, Johnson Casey S, Buller Mark, Liu Jian et al (2004) ACAM2000 Clonal vero cell culture vaccinia virus (New York City Board of Health Strain)—a second-generation smallpox vaccine for biological defense. Int J Infect Dis 8:S31-44. 10.1016/j.ijid.2004.09.002</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7110559</ArticleId><ArticleId IdType="pubmed">15491873</ArticleId></ArticleIdList></Reference><Reference><Citation>Moyle PM, Toth I (2013) Modern subunit vaccines: development, components, and research opportunities. ChemMedChem 8(3):360–376. 10.1002/cmdc.201200487</Citation><ArticleIdList><ArticleId IdType="pubmed">23316023</ArticleId></ArticleIdList></Reference><Reference><Citation>Murata H, Peden K, Lewis AM (2008) Identification of a mutation in the SV40 capsid protein VP1 that influences plaque morphology, vacuolization, and receptor usage. Virology 370(2):343–351. 10.1016/j.virol.2007.08.040</Citation><ArticleIdList><ArticleId IdType="pubmed">17936868</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy FA, Osburn BI (2005) Adventitious agents and smallpox vaccine in strategic national stockpile. Emerg Infect Dis 11(7):1086–1089. 10.3201/eid1107.050277</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3371778</ArticleId><ArticleId IdType="pubmed">16022785</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagel J (1967) Isolation from bordetella pertussis of protective antigen free from toxic activity and histamine sensitizing factor. Nature 214(5083):96–97. 10.1038/214096a0</Citation><ArticleIdList><ArticleId IdType="pubmed">4291816</ArticleId></ArticleIdList></Reference><Reference><Citation>Neff BJ, Weibel RE, Villarejos VM, Buynak EB, McLean AA, Morton DH, Wolanski BS, Hilleman MR (1981) Clinical and laboratory studies of KMcC strain live attenuated varicella virus. Proc Soc Exp Biol Med 166(3):339–347. 10.3181/00379727-166-41071</Citation><ArticleIdList><ArticleId IdType="pubmed">6259644</ArticleId></ArticleIdList></Reference><Reference><Citation>Oda M, Izumiya K, Sato Y, Hirayama M (1983) Transplacental and transcolostral immunity to pertussis in a mouse model using acellular pertussis vaccine. J Infect Dis 148(1):138–145. 10.1093/infdis/148.1.138</Citation><ArticleIdList><ArticleId IdType="pubmed">6309992</ArticleId></ArticleIdList></Reference><Reference><Citation>Ogden, Shawnna A., John T. Ludlow, and Khalid Alsayouri (2024) “Diphtheria Tetanus Pertussis (DTaP) vaccine.” In StatPearls. Treasure Island (FL): StatPearls Publishing. http://www.ncbi.nlm.nih.gov/books/NBK545173/</Citation><ArticleIdList><ArticleId IdType="pubmed">31424757</ArticleId></ArticleIdList></Reference><Reference><Citation>Okazaki W, Purchase HG, Burmester BR (1970) Protection against Marek’s disease by vaccination with a herpesvirus of Turkeys. Avian Dis 14(2):413–429</Citation><ArticleIdList><ArticleId IdType="pubmed">4913403</ArticleId></ArticleIdList></Reference><Reference><Citation>Park A-R, Jang S-W, Kim J-S, Park Y-G, Koo B-S, Lee H-C (2018) Efficient recovery of recombinant CRM197 expressed as inclusion bodies in E. Coli. PLOS One 13(7):e0201060. 10.1371/journal.pone.0201060</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6051658</ArticleId><ArticleId IdType="pubmed">30021008</ArticleId></ArticleIdList></Reference><Reference><Citation>Parry CM, Ribeiro I, Walia K, Rupali P, Baker S, Basnyat B (2019) Multidrug resistant enteric fever in South Asia: unmet medical needs and opportunities. BMJ (Clinical Research Ed) 364(January):k5322. 10.1136/bmj.k5322</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6340381</ArticleId><ArticleId IdType="pubmed">30670452</ArticleId></ArticleIdList></Reference><Reference><Citation>Parween F, Yadav J, Qadri A (2019) The virulence polysaccharide of Salmonella Typhi suppresses activation of rho family GTPases to limit inflammatory responses from epithelial cells. Front Cell Infect Microbiol 9(May):141. 10.3389/fcimb.2019.00141</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6517557</ArticleId><ArticleId IdType="pubmed">31134159</ArticleId></ArticleIdList></Reference><Reference><Citation>Pettersson J, Holmström A, Hill J, Leary S, Frithz-Lindsten E, von Euler-Matell A, Carlsson E, Titball R, Forsberg A, Wolf-Watz H (1999) The V-Antigen of yersinia is surface exposed before target cell contact and involved in virulence protein translocation. Mol Microbiol 32(5):961–976. 10.1046/j.1365-2958.1999.01408.x</Citation><ArticleIdList><ArticleId IdType="pubmed">10361299</ArticleId></ArticleIdList></Reference><Reference><Citation>Pollard AJ, Maiden MCJ (2001) Meningococcal vaccines: methods and protocols. Humana Press, Totowa, N.J.</Citation></Reference><Reference><Citation>Provost PJ, Hilleman MR (1978) An inactivated Hepatitis A virus vaccine prepared from infected marmoset liver. Proc Soc Exp Biol Med 159(2):201–3. 10.3181/00379727-159-40314</Citation><ArticleIdList><ArticleId IdType="pubmed">213786</ArticleId></ArticleIdList></Reference><Reference><Citation>Provost PJ, Hilleman MR (1979) Propagation of human hepatitis A virus in cell culture in vitro. Proc Soc Exp Biol Med 160(2):213–221</Citation><ArticleIdList><ArticleId IdType="pubmed">217023</ArticleId></ArticleIdList></Reference><Reference><Citation>Provost PJ, Ittensohn OL, Villarejos VM, Arguedas JA, Hilleman MR (1973) Etiologic relationship of Marmoset-Propagated CR326 Hepatitis A virus to hepatitis in man. Exp Biol Med 142(4):1257–67. 10.3181/00379727-142-37220</Citation><ArticleIdList><ArticleId IdType="pubmed">4632938</ArticleId></ArticleIdList></Reference><Reference><Citation>Qadri, Firdausi, John D. Clemens, and Jan Holmgren (2020) “Cholera immunity and development and use of oral cholera vaccines for disease control.” In Mucosal Vaccines. Elsevier. Pp 537–561. 10.1016/B978-0-12-811924-2.00031-6.</Citation></Reference><Reference><Citation>Saha A, Chowdhury MI, Farhana Khanam Md, Bhuiyan S, Chowdhury F, Khan AI, Khan IA et al (2011) Safety and immunogenicity study of a killed bivalent (O1 and O139) Whole-cell oral cholera vaccine Shanchol, in Bangladeshi adults and children as young as 1 year of age. Vaccine 29(46):8285–8292. 10.1016/j.vaccine.2011.08.108</Citation><ArticleIdList><ArticleId IdType="pubmed">21907255</ArticleId></ArticleIdList></Reference><Reference><Citation>Saha A, Khan A, Salma U, Jahan N, Bhuiyan TR, Chowdhury F, Khan AI et al (2016) The oral cholera vaccine Shanchol™ when stored at elevated temperatures maintains the safety and immunogenicity profile in Bangladeshi participants. Vaccine 34(13):1551–1558. 10.1016/j.vaccine.2016.02.020</Citation><ArticleIdList><ArticleId IdType="pubmed">26896684</ArticleId></ArticleIdList></Reference><Reference><Citation>Sahastrabuddhe S, Carbis R, Wierzba TF, Leon Ochiai R (2013) Increasing rates of Salmonella Paratyphi A and the current status of its vaccine development. Expert Rev Vaccines 12(9):1021–1031. 10.1586/14760584.2013.825450</Citation><ArticleIdList><ArticleId IdType="pubmed">24053396</ArticleId></ArticleIdList></Reference><Reference><Citation>Saleh A, Qamar S, Tekin A, Singh R, Kashyap R (2021) Vaccine development throughout history. Cureus. 10.7759/cureus.16635</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8386248</ArticleId><ArticleId IdType="pubmed">34462676</ArticleId></ArticleIdList></Reference><Reference><Citation>Santosham M, Wolff M, Reid R, Hohenboken M, Bateman M, Goepp J, Cortese M, Sack D, Hill J, Newcomer W (1991) The efficacy in navajo infants of a conjugate vaccine consisting of Haemophilus Influenzae Type b Polysaccharide and Neisseria meningitidis outer-membrane protein complex. N Engl J Med 324(25):1767–1772. 10.1056/NEJM199106203242503</Citation><ArticleIdList><ArticleId IdType="pubmed">1903846</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayeed MA, Bufano MK, Xu P, Eckhoff G, Charles RC, Alam MM, Ryan ET (2015) A cholera conjugate vaccine containing O-specific polysaccharide (OSP) of V. cholerae O1 Inaba and recombinant fragment of tetanus toxin heavy chain (OSP: rTTHc) induces serum, memory and lamina proprial responses against OSP and is protective in mice. PLoS Neglected Trop Dis 9(7):e0003881</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4495926</ArticleId><ArticleId IdType="pubmed">26154421</ArticleId></ArticleIdList></Reference><Reference><Citation>Schild S, Nelson EJ, Camilli A (2008) Immunization with vibrio cholerae outer membrane vesicles induces protective immunity in mice. Infect Immun 76(10):4554–4563. 10.1128/IAI.00532-08</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2546833</ArticleId><ArticleId IdType="pubmed">18678672</ArticleId></ArticleIdList></Reference><Reference><Citation>Simanjuntak CH, Paleologo FP, Punjabi NH, Darmowigoto R, Null Soeprawoto H, Totosudirjo P, Haryanto E, SuprijantoWitham ND, Hoffman SL (1991) Oral immunisation against typhoid fever in Indonesia with Ty21a vaccine. Lancet (London, England) 338(8774):1055–59. 10.1016/0140-6736(91)91910-m</Citation><ArticleIdList><ArticleId IdType="pubmed">1681365</ArticleId></ArticleIdList></Reference><Reference><Citation>Simon R, Wang JY, Boyd MA, Tulapurkar ME, Ramachandran G, Tennant SM, Pasetti M, Galen JE, Levine MM (2013) Sustained protection in mice immunized with fractional doses of Salmonella Enteritidis core and O Polysaccharide-Flagellin Glycoconjugates. PLoS One 8(5):e64680. 10.1371/journal.pone.0064680</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3669428</ArticleId><ArticleId IdType="pubmed">23741368</ArticleId></ArticleIdList></Reference><Reference><Citation>Sridhar S (2015) Clinical development of ebola vaccines. Therap Adv Vaccines 3(5–6):125–138. 10.1177/2051013615611017</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4667768</ArticleId><ArticleId IdType="pubmed">26668751</ArticleId></ArticleIdList></Reference><Reference><Citation>Steele AD, Hay DC, Burgess ZD, Carey ME, Zaidi AKM (2016) Challenges and opportunities for typhoid fever control: a call for coordinated action. Clin Infect Dis 62(suppl 1):S4-8. 10.1093/cid/civ976</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4772836</ArticleId><ArticleId IdType="pubmed">26933019</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokes Joseph, Weibel Robert, Halenda Ronald, Reilly Charles M, Hilleman Maurice R (1962) Studies of live attenuated measles virus vaccine in man: I. Clinical aspects. Am J Public Health Nations Health 52:29–43. 10.2105/AJPH.52.Suppl_2.29</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1522577</ArticleId><ArticleId IdType="pubmed">13917383</ArticleId></ArticleIdList></Reference><Reference><Citation>Stokes J, Weibel RE, Villarejos VM, Arguedas JA, Buynak EB, Hilleman MR (1971) Trivalent combined measles-mumps-rubella vaccine. findings in clinical-laboratory studies. JAMA 218(1):57–61</Citation><ArticleIdList><ArticleId IdType="pubmed">4937795</ArticleId></ArticleIdList></Reference><Reference><Citation>Syed KA, Saluja T, Cho H, Hsiao A, Hanif Shaikh T, Wartel A, Mogasale V et al (2020) Review on the recent advances on typhoid vaccine development and challenges ahead. Clin Infect Dis 71(2):S141–50. 10.1093/cid/ciaa504</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7388714</ArticleId><ArticleId IdType="pubmed">32725225</ArticleId></ArticleIdList></Reference><Reference><Citation>Szmuness W, Stevens CE, Zang EA, Harley EJ, Kellner A (1981) A controlled clinical trial of the efficacy of the Hepatitis B vaccine (Heptavax B): a final report. Hepatology 1(5):377–385. 10.1002/hep.1840010502</Citation><ArticleIdList><ArticleId IdType="pubmed">7030902</ArticleId></ArticleIdList></Reference><Reference><Citation>Szu SC (2013) Development of Vi conjugate—a new generation of typhoid vaccine. Expert Rev Vaccines 12(11):1273–1286. 10.1586/14760584.2013.845529</Citation><ArticleIdList><ArticleId IdType="pubmed">24156285</ArticleId></ArticleIdList></Reference><Reference><Citation>Tacket CO, Sztein MB, Wasserman SS, Losonsky G, Kotloff KL, Wyant TL, Nataro JP et al (2000) Phase 2 clinical trial of attenuated Salmonella Enterica Serovar Typhi oral live vector vaccine CVD 908- htrA in U.S. volunteers. Infection and Immunity 68(3):1196–1201. 10.1128/IAI.68.3.1196-1201.2000</Citation><ArticleIdList><ArticleId IdType="pmc">PMC97267</ArticleId><ArticleId IdType="pubmed">10678926</ArticleId></ArticleIdList></Reference><Reference><Citation>Taha M, Amira KA, Mahmoud AM, Elkasaby MH, Nguyen D, Ahmed R, Pari Patel D, Bonilla-Aldana K, Luna C, Rodriguez-Morales AJ (2024) Safety and immunogenicity of Vi-Diphtheria toxoid typhoid conjugate vaccine among children below 2 years: a systematic review and meta-analysis. Front Microbiol 15(April):1385834. 10.3389/fmicb.2024.1385834</Citation><ArticleIdList><ArticleId IdType="pmc">PMC11026668</ArticleId><ArticleId IdType="pubmed">38646637</ArticleId></ArticleIdList></Reference><Reference><Citation>Tai JY, Vella PP, McLean AA, Woodhour AF, McAleer WJ, Sha A, Dennis-Sykes C, Hilleman MR (1987) Haemophilus influenzae Type b polysaccharide-protein conjugate vaccine. Exp Biol Med 184(2):154–161. 10.3181/00379727-184-42460</Citation><ArticleIdList><ArticleId IdType="pubmed">3543938</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi M, Asano Y, Kamiya H, Baba K (1985) Varicella vaccine: case studies. Microbiol Sci 2(8):249–254</Citation><ArticleIdList><ArticleId IdType="pubmed">2856380</ArticleId></ArticleIdList></Reference><Reference><Citation>Tariq H, Batool S, Asif S, Ali M, Abbasi BH (2022) Virus-like particles: revolutionary platforms for developing vaccines against emerging infectious diseases. Front Microbiol 12(January):790121. 10.3389/fmicb.2021.790121</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8761975</ArticleId><ArticleId IdType="pubmed">35046918</ArticleId></ArticleIdList></Reference><Reference><Citation>Tennant SM, Levine MM (2015) Live attenuated vaccines for invasive salmonella infections. Vaccine 33(June):C36-41. 10.1016/j.vaccine.2015.04.029</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4469493</ArticleId><ArticleId IdType="pubmed">25902362</ArticleId></ArticleIdList></Reference><Reference><Citation>Thanawastien A, Cartee RT, Griffin TJ, Killeen KP, Mekalanos JJ (2015) Conjugate-like immunogens produced as protein capsular matrix vaccines. Proc National Acad Sci 112(10):E1143–E1151. 10.1073/pnas.1425005112</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4364189</ArticleId><ArticleId IdType="pubmed">25699685</ArticleId></ArticleIdList></Reference><Reference><Citation>Thiem A (2011) Conditions of intergovernmental armaments cooperation in Western Europe, 1996–2006. Eur Polit Sci Rev 3(1)1–33</Citation></Reference><Reference><Citation>Thomas F, Magill TP (1936) Vaccination of human subjects with virus of human influenza. Exp Biol Med 33(4):604–606. 10.3181/00379727-33-8467P</Citation></Reference><Reference><Citation>Titball RW, Howells AM, Oyston PC, Williamson ED (1997) Expression of the Yersinia Pestis Capsular Antigen (F1 Antigen) on the surface of an aroa mutant of Salmonella Typhimurium induces high levels of protection against plague. Infect Immun 65(5):1926–1930. 10.1128/iai.65.5.1926-1930.1997</Citation><ArticleIdList><ArticleId IdType="pmc">PMC175242</ArticleId><ArticleId IdType="pubmed">9125581</ArticleId></ArticleIdList></Reference><Reference><Citation>Tran TH, Nguyen TD, Nguyen TT, Ninh TTV, Tran NBC, Nguyen VMH, Tran TTN et al (2010) A randomised trial evaluating the safety and immunogenicity of the novel single oral dose typhoid vaccine M01ZH09 in healthy Vietnamese children. PLoS One 5(7):e11778. 10.1371/journal.pone.0011778</Citation><ArticleIdList><ArticleId IdType="pmc">PMC2909895</ArticleId><ArticleId IdType="pubmed">20668668</ArticleId></ArticleIdList></Reference><Reference><Citation>“Typhoid vaccines: WHO position paper.” (2008) Releve Epidemiologique Hebdomadaire. 83(6): 49–59</Citation><ArticleIdList><ArticleId IdType="pubmed">18260212</ArticleId></ArticleIdList></Reference><Reference><Citation>Ura T, Okuda K, Shimada M (2014) Developments in viral vector-based vaccines. Vaccines 2(3):624–641. 10.3390/vaccines2030624</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4494222</ArticleId><ArticleId IdType="pubmed">26344749</ArticleId></ArticleIdList></Reference><Reference><Citation>Valenzuela P, Medina A, Rutter WJ, Ammerer G, Hall BD (1982) Synthesis and assembly of Hepatitis B virus surface antigen particles in yeast. Nature 298(5872):347–350. 10.1038/298347a0</Citation><ArticleIdList><ArticleId IdType="pubmed">7045698</ArticleId></ArticleIdList></Reference><Reference><Citation>Van Loon FPL, Clemens JD, Chakraborty J, Rao MR, Kay BA, Sack DA, Yunus Md, Ali Md, Svennerholm A-M, Holmgren J (1996) Field trial of inactivated oral cholera vaccines in Bangladesh: results from 5 years of follow-up. Vaccine 14(2):162–166. 10.1016/0264-410X(95)00122-H</Citation><ArticleIdList><ArticleId IdType="pubmed">8852414</ArticleId></ArticleIdList></Reference><Reference><Citation>Vashishtha VM, Kalra A (2020) The need and the issues related to new-generation typhoid conjugate vaccines in India. Indian J Med Res 151(1):22–34. 10.4103/ijmr.IJMR_1890_17</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7055164</ArticleId><ArticleId IdType="pubmed">32134011</ArticleId></ArticleIdList></Reference><Reference><Citation>Wahdan MH, Serie C, Cerisier Y, Sallam S, Germanier R (1982) A controlled field trial of live Salmonella Typhi strain Ty 21a oral vaccine against typhoid: three-year results. J Infect Dis 145(3):292–295. 10.1093/infdis/145.3.292</Citation><ArticleIdList><ArticleId IdType="pubmed">7037982</ArticleId></ArticleIdList></Reference><Reference><Citation>Weltzin R, Liu J, Pugachev KV, Myers GA, Coughlin B, Blum PS, Nichols R et al (2003) Clonal vaccinia virus grown in cell culture as a new smallpox vaccine. Nat Med 9(9):1125–1130. 10.1038/nm916</Citation><ArticleIdList><ArticleId IdType="pubmed">12925845</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson ED, Eley SM, Stagg AJ, Green M, Russell P, Titball RW (2000) A single dose sub-unit vaccine protects against pneumonic plague. Vaccine 19(4–5):566–571. 10.1016/S0264-410X(00)00159-6</Citation><ArticleIdList><ArticleId IdType="pubmed">11027822</ArticleId></ArticleIdList></Reference><Reference><Citation>Williamson ED, Vesey PM, Gillhespy KJ, Eley SM, Green M, Titball RW (2001) An IgG1 Titre to the F1 and V antigens correlates with protection against plague in the mouse model. Clin Exp Immunol 116(1):107–114. 10.1046/j.1365-2249.1999.00859.x</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1905224</ArticleId><ArticleId IdType="pubmed">10209513</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong, Karen K., Erin Burdette, Barbara E. Mahon, Eric D. Mintz, Edward T. Ryan, and Arthur L. Reingold (2017) “Recommendations of the advisory committee on immunization practices for use of cholera vaccine.” MMWR. Morbidity and Mortality Weekly Report 66 (18): 482–85. 10.15585/mmwr.mm6618a6.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5657988</ArticleId><ArticleId IdType="pubmed">28493859</ArticleId></ArticleIdList></Reference><Reference><Citation>Wyatt LS, Earl PL, Eller LA, Moss B (2004) Highly attenuated smallpox vaccine protects mice with and without immune deficiencies against pathogenic vaccinia virus challenge. Proc Natl Acad Sci 101(13):4590–4595. 10.1073/pnas.0401165101</Citation><ArticleIdList><ArticleId IdType="pmc">PMC384791</ArticleId><ArticleId IdType="pubmed">15070762</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J, Zhao S, Junxian Ou, Zhang J, Lan W, Guan W, Xiaowei Wu et al (2020) COVID-19: coronavirus vaccine development updates. Front Immunol 11(December):602256. 10.3389/fimmu.2020.602256</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7785583</ArticleId><ArticleId IdType="pubmed">33424848</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F, Reef S, Massoudi M, Yusuf HR, Bardenheier B, Zimmerman L (2004) An economic analysis of the current universal 2-Dose measles-mumps-rubella vaccination program in the United States. J Infect Dis 189(1):S131-45. 10.1086/378987</Citation><ArticleIdList><ArticleId IdType="pubmed">15106102</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou P, Yang X-L, Wang X-G, Ben Hu, Zhang L, Zhang W, Si H-R et al (2020) A pneumonia outbreak associated with a new coronavirus of probable bat origin. Nature 579(7798):270–273. 10.1038/s41586-020-2012-7</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7095418</ArticleId><ArticleId IdType="pubmed">32015507</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>